Medical Device Companies in Buffalo Niagara: 14 Named Firms

Buffalo Niagara’s medical device sector is not one anchor employer with suppliers around it. It is a spread of contract manufacturers, device makers, diagnostics firms and startups, most of them known inside the industry and almost none of them known outside it.

Which medical device companies are in Buffalo Niagara?

Fourteen named companies operate here across contract manufacturing, pharmaceutical processing, diagnostics and device innovation, and every one of them is documented on this site.

The list matters more than a sector statistic, because a peer already operating in a region is the strongest risk-reduction signal there is for a company evaluating it. Grouped by what they actually do:

• Contract and precision manufacturing: Harmac Medical Products, Integer, Viant, MedBio.
• Pharmaceutical and aseptic processing: Thermo Fisher Scientific, Fresenius Kabi, IMA Life.
• Diagnostics and laboratory: Aesku NY, FroggaBio, Ivoclar.
• Device innovators: PatCom Medical, LegWorks, Garwood Medical Devices, Polymer Medical.

The companies, and what they did here

Contract and precision manufacturing

Harmac Medical Products is a single-use device manufacturer working across the full product life cycle. Integer and Viant both run device manufacturing operations in the region. MedBio expanded into Orchard Park with 45 new jobs and $14.3 million invested.

Pharmaceutical and aseptic processing

Thermo Fisher Scientific and Fresenius Kabi both operate here. IMA Life, a division of Italy’s IMA Group, builds aseptic processing, filling and freeze-drying equipment. Its most recent local expansion is a 120,000 square foot facility in North Tonawanda: $27.6 million, 30 new jobs on top of an existing workforce of 176, with room to grow by up to 230 more.

Diagnostics and laboratory

Aesku NY is the US operation of a German autoimmune diagnostics firm. FroggaBio, headquartered in Toronto, distributes laboratory products and instruments. Ivoclar operates here in dental.

Device innovators

PatCom Medical is a Canadian company whose endoscopes and patented Esophageal Introducer improve testing for swallowing disorders. LegWorks makes the All-Terrain Knee, a prosthetic knee joint aimed at making functional prosthetics affordable globally. Garwood Medical Devices is moving to Northland Avenue. Polymer Medical committed $1.5 million and 15 new jobs in Western New York.

Two things stand out from that list, and neither is a statistic. Several of these are Canadian or European firms that chose Buffalo Niagara for their US operation, and several are small firms that scaled here rather than relocating once they grew, which is the harder thing for a region to achieve.

What the cluster provides

A concentrated medical campus

The Buffalo Niagara Medical Campus is a 120-acre research and medical park in downtown Buffalo with over 200 private-sector companies and around 20,000 people working on it. It includes hospitals, research centers and incubator space, which matters for a device company that needs clinical proximity during development. We covered what is happening on the campus separately.

Clinical and research partners

Roswell Park Comprehensive Cancer Center is here, as is the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and the Hauptman-Woodward Medical Research Institute, founded by a Nobel laureate in chemistry. The UB New York State Center of Excellence in Bioinformatics and Life Sciences hosts a $100 million collaboration in genomic medicine.

Workforce depth in the specific fields

The region ranks fourth in America for the per-capita share of life sciences workers, and the sector accounts for 1.5 percent of all employment here against a national average of 1.1 percent. Nearly 25 percent of the degrees conferred by regional colleges each year are in life sciences and related fields.

Capital

More than $530 million in angel and venture capital has been invested in the region’s research and development sector, with two thirds of it going to life sciences and health sciences.

Manufacturing economics, which device companies underweight

Device manufacturing is manufacturing. Manufacturers here pay no New York State corporate income tax, no inventory or personal property tax and no sales tax on production or research equipment, with a 5 percent refundable investment tax credit on capital expenditure and industrial electricity about 15 percent below the national average. New York’s Employee Training Incentive Program also covers 50 percent of eligible training costs up to $10,000 per employee, and explicitly includes approved internship programs in life sciences at 50 percent of the stipend up to $3,000 per intern, per the New York State Department of Taxation and Finance.

The cross-border angle

PatCom Medical and FroggaBio are both Canadian companies that established US operations here, and that is not a coincidence. For a Canadian device firm, US market access usually means a US entity, and doing it 30 minutes from the border means the existing team keeps running both operations. If that is your situation, how we work with Canadian companies is the better starting point, and the eligibility question is answered separately.

Questions device companies ask

Is there contract manufacturing capacity here, or would we build our own?

Both routes exist. Harmac, Integer and Viant are established contract manufacturers, and companies including MedBio and Polymer Medical have built their own. Which makes sense depends on volume and on whether the process is your differentiator.

Can we get cleanroom space, or does it have to be built?

It varies by specification, and it is the question worth asking early because it changes the timeline more than anything else. Tell us the classification and the square footage and we will find out what exists before you plan a build.

How close is clinical partnership, really?

The medical campus is 120 acres in downtown Buffalo with Roswell Park, UB’s medical school and 200-plus companies on it. For a device company needing clinical input during development, that concentration is the argument, not the postcode.

What does the region not have?

It is not Boston or the Bay Area on late-stage venture capital. The $530 million figure is real and two thirds of it goes to this sector, but a company whose plan depends on a large local Series C should test that assumption rather than take it from a regional page. Companies here often raise elsewhere and build here, which is a legitimate model and worth planning for deliberately.

Where to go deeper

Our medical device industry overview carries the sector data in one document, and the life sciences sector page covers the wider picture.

If you are weighing a device operation here, we will pull the labor data for your specific roles, find the space, handle the incentive applications and make the introductions to the campus and the clinical partners. Free and confidential, whether or not you choose the region.